DBV Technologies (CHIX:DBVP) ROE % Adjusted to Book Value: -16.72% (As of Mar. 2026)


CHIX:DBVP DBV Technologies SA CHIX:DBVP
31 GF Score
Price €2.91
! 1 Warning Sign
View Full Analysis

What is DBV Technologies ROE % Adjusted to Book Value?

DBV Technologies CHIX:DBVP 31 ROE % Adjusted to Book Value is -16.72% as of Mar. 2026. GuruFocus rates CHIX:DBVP with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

DBV Technologies's ROE % for the quarter that ended in Mar. 2026 was -101.65%. DBV Technologies's PB Ratio for the quarter that ended in Mar. 2026 was 6.08. DBV Technologies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -16.72%.

DBV Technologies ROE % Adjusted to Book Value Related Terms

DBV Technologies ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for DBV Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DBV Technologies ROE % Adjusted to Book Value Chart

DBV Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.13 -46.19 -15.83 -9.94 -24.32

DBV Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.02 -56.85 -38.67 -26.72 -16.72

CHIX:DBVP vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, DBV Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where DBV Technologies's ROE % Adjusted to Book Value falls into.


CHIX:DBVP
31GF Score
DBV Technologies SA CHIX:DBVP
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DBV Technologies ROE % Adjusted to Book Value Calculation

DBV Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-147.39% / 6.06
=-24.32%

DBV Technologies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-101.65% / 6.08
=-16.72%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -16.72% mean?
DBV Technologies (CHIX:DBVP) has a ROE % Adjusted to Book Value of -16.72% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on DBV Technologies and its competitors.
Is DBV Technologies' ROE % Adjusted to Book Value too high?
DBV Technologies' current ROE % Adjusted to Book Value is -16.72%. Overall, DBV Technologies has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' ROE % Adjusted to Book Value compare to VRTX and REGN?
DBV Technologies' ROE % Adjusted to Book Value of -16.72% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on DBV Technologies and its competitors. DBV Technologies's current ROE % Adjusted to Book Value is -16.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (CHIX:DBVP) has a current ROE % Adjusted to Book Value of -16.72%. The current ROE % Adjusted to Book Value is -16.72%. DBV Technologies' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For DBV Technologies (CHIX:DBVP), the current ROE % Adjusted to Book Value is -16.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DBV Technologies Business Description

Address 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score

Get the complete analysis for CHIX:DBVP

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.91
Price